TY  - JOUR

T1  - A randomized phase II study of erdafitinib (ERDA) versus intravesical chemotherapy (IC) in patients with high-risk nonmuscle invasive bladder cancer (HR-NMIBC) with FGFR mutations or fusions, who recurred after Bacillus Calmette-Guérin (BCG) therapy.

JO  - Journal of Clinical Oncology

PY  - 2020/02/20

AU  - Steinberg GD

AU  - Palou-Redorta J

AU  - Gschwend JE

AU  - Tran B

AU  - Loriot Y

AU  - Daneshmand S

AU  - Roupret M

AU  - Santiago-Walker AE

AU  - Switzky JC

AU  - Major C

AU  - Baig M et al

ED  - 

DO  - DOI: 10.1200/jco.2020.38.6_suppl.tps603

PB  - American Society of Clinical Oncology (ASCO)

VL  - 38

IS  - 6_suppl

SP  - TPS603

EP  - TPS603

Y2  - 2024/12/22

ER  -